TrovaGene Inc (NASDAQ:TROV) has been given an average rating of “Buy” by the six research firms that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $4.75.
TROV has been the topic of several research reports. Maxim Group upgraded shares of TrovaGene from a “hold” rating to a “buy” rating in a report on Friday, June 15th. Zacks Investment Research upgraded shares of TrovaGene from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a report on Thursday, June 7th. HC Wainwright set a $7.00 target price on shares of TrovaGene and gave the stock a “buy” rating in a report on Monday, June 4th. Finally, ValuEngine upgraded shares of TrovaGene from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd.
In other TrovaGene news, Director Rodney S. Markin bought 41,200 shares of the stock in a transaction that occurred on Wednesday, June 20th. The shares were bought at an average price of $0.85 per share, for a total transaction of $35,020.00. Following the acquisition, the director now directly owns 63,810 shares of the company’s stock, valued at approximately $54,238.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 8.30% of the company’s stock.
Shares of NASDAQ TROV traded down $0.01 during trading on Friday, hitting $0.80. 1,400 shares of the company traded hands, compared to its average volume of 1,318,502. TrovaGene has a fifty-two week low of $0.79 and a fifty-two week high of $19.56. The firm has a market capitalization of $4.01 million, a P/E ratio of -0.13 and a beta of -0.14.
TrovaGene (NASDAQ:TROV) last announced its quarterly earnings data on Tuesday, May 8th. The medical research company reported ($1.08) earnings per share for the quarter, beating the consensus estimate of ($1.44) by $0.36. TrovaGene had a negative net margin of 3,861.57% and a negative return on equity of 342.47%. The firm had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.10 million. sell-side analysts forecast that TrovaGene will post -1.15 earnings per share for the current fiscal year.
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.